Palatin Technologies is a biopharmaceutical company headquartered in New Jersey that creates targeted and receptor-specific therapeutic solutions to treat various diseases. Its lead product, Vyleesi, is a melanocortin receptor (MCr) agonist used to treat premenopausal women with hypoactive sexual desire disorder. The company is also developing several other products, including PL8177 and PL9643 for inflammatory bowel diseases and anti-inflammatory ocular indications, respectively.